Do Ehrlichia chaffeensis and Rickettsia typhi IgG indicate prior exposure rather than active infection?

At age 83, distinguishing remote exposure from an acute tick- or flea-borne illness is clinically important, but the serologic interpretation is the same: isolated IgG is not proof of active infection.

Clinical interpretation

• Ehrlichia chaffeensis IgG supports prior antigenic exposure/infection; IgG may remain elevated for many months after illness. A single result—even a titer ≥1:128—is only presumptive evidence and cannot confirm acute ehrlichiosis.
• Rickettsia typhi IgG likewise supports previous exposure/infection, but anti-R. typhi IgG can persist for months to years. A single positive or stable titer cannot distinguish remote infection from current murine typhus.
• Therefore, neither IgG result alone establishes that either organism explains current symptoms or requires treatment in the absence of a compatible acute clinical syndrome.

Confirmation and diagnostic timing

• For either infection, confirmation of recent infection relies on paired acute and convalescent IgG specimens, generally collected 2–10 weeks apart, demonstrating seroconversion or a ≥4-fold rise in titer.
• Whole-blood PCR can support active ehrlichiosis, with greatest yield in the first week of illness and before or shortly after antibiotics. A negative PCR does not exclude infection, particularly after treatment. Early serology can also be negative before antibodies develop.

Specificity and mechanism

• Serology detects an antibody response, which can outlast pathogen clearance; this is why persistent IgG is an exposure marker rather than a direct measure of ongoing infection.
• Species attribution is imperfect: Ehrlichia antibodies can cross-react with Anaplasma antigens, while R. typhi antibodies commonly cross-react with R. prowazekii.

Bottom line

• The claim is supported: positive E. chaffeensis and R. typhi IgG indicate prior related immune exposure but, without paired rising titers, seroconversion, or appropriately timed molecular evidence in a compatible illness, do not establish current active infection.